79 related articles for article (PubMed ID: 2462651)
1. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
Akaza H; Isurugi K; Oishi Y; Kitajima K; Sawamura Y; Baba S; Yoshida K; Otani M; Harada M; Gunji A
Jpn J Clin Oncol; 1988 Dec; 18(4):343-55. PubMed ID: 2462651
[TBL] [Abstract][Full Text] [Related]
2. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)].
Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M
Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of prostatic cancer].
Hirao Y; Kubota K; Yoshie T; Tabata S; Samma S; Ozono S; Okajima E; Sasaki K; Yoshikawa M; Tsumatani K
Hinyokika Kiyo; 1991 Aug; 37(8):817-24. PubMed ID: 1720273
[TBL] [Abstract][Full Text] [Related]
4. [Treatment for hormone-refractory or relapsing prostatic cancer].
Hirao Y; Ozono S; Okajima E
Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
[TBL] [Abstract][Full Text] [Related]
5. [Use of arterial infusion of neocarzinostatin with or without combination chemotherapy as a treatment of carcinoma of the prostate].
Yuasa M; Numata A; Tanaka T; Kawanishi Y; Yamamoto A; Imagawa A
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2325-30. PubMed ID: 2425748
[TBL] [Abstract][Full Text] [Related]
6. [A case of advanced prostatic cancer in a 44-year-old treated effectively with combination chemo-endocrine therapy].
Araki S; Kusuyama H; Kato M; Okada K
Hinyokika Kiyo; 1990 Apr; 36(4):465-9. PubMed ID: 1696064
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
8. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of hormonally unresponsive prostatic carcinoma.
deKernion JB; Lindner A
Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
Asakawa M; Wada S; Hayahara N; Yayumoto R; Kishimoto T; Maekawa M; Morikawa Y; Kawakita J; Umeda M; Horii A
Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
[TBL] [Abstract][Full Text] [Related]
12. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Murphy GP; Slack NH; Mittelman A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
[No Abstract] [Full Text] [Related]
13. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
Vahlensieck W; Wegner G
Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
[TBL] [Abstract][Full Text] [Related]
14. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
17. [The phase IV studies with Estracyt in prostatic cancer--supplementary report: results of long-term therapy].
Ohhori T; Kubo T; Kawamura S; Suzuki T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1992 Aug; 38(8):979-87. PubMed ID: 1414749
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
19. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
